#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach


Autoři: Alessio Bruni aff001;  Niccolò Giaj-Levra aff002;  Patrizia Ciammella aff003;  Virginia Maragna aff004;  Katia Ferrari aff005;  Viola Bonti aff005;  Francesco Grossi aff006;  Stefania Greco aff007;  Carlo Greco aff008;  Paolo Borghetti aff009;  Davide Franceschini aff010;  Enrica Capelletto aff011;  Marco Perna aff004;  Giuseppe Banna aff012;  Stefano Vagge aff013;  Editta Baldini aff014;  Emilio Bria aff015;  Andrea Botti aff016;  Marcello Tiseo aff017;  Massimiliano Paci aff018;  Maria Taraborrelli aff019;  Venerino Poletti aff020;  Pierluigi Granone aff022;  Umberto Ricardi aff023;  Silvia Novello aff011;  Vieri Scotti aff004
Působiště autorů: Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy aff001;  Department of Advanced Radiation Oncology, IRCCS Sacro Cuore–Don Calabria Hospital, Negrar, Verona, Italy aff002;  Radiation Therapy Unit, Department of Oncology and Advanced Technology, AUSL-IRCCS, Reggio Emilia, Italy aff003;  Radiation Therapy Unit, Department of Oncology, Careggi University Hospital, Firenze, Italy aff004;  Section of Respiratory Medicine, Careggi University Hospital, Firenze, Italy aff005;  UOC Oncologia Medica Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy aff006;  UOSD of Oncologic Pneumology, San Camillo Forlanini Hospital, Rome, Italy aff007;  Department of Radiation Oncology, Campus Bio-Medico University, Rome, Italy aff008;  Radiation Oncology Department University and Spedali Civili, Brescia, Italy aff009;  Department of Radiotherapy and Radiosurgery, Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy aff010;  Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy aff011;  Oncology Department, Ospedale Cannizzaro, Catania, Italy aff012;  Department of Radiation Oncology, Azienda Ospedaliera Universitaria San Martino di Genova—IST, Istituto Nazionale Ricerca sul Cancro, Genoa, Italy aff013;  UOC Oncologia Medica Ospedale San Luca, Lucca, Italy aff014;  U.O.C. Oncologia Medica, Comprehensive Cancer Center—Fondazione Policlinico Universitario A. Gemelli, IRCCS—Università Cattolica del Sacro Cuore, Roma, Italy aff015;  Medical Physics Unit, Department of Oncology and Advanced Technology, AUSL-IRCCS, Reggio Emilia, Italy aff016;  Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, Parma, Italy aff017;  Division of Thoracic Surgery, Azienda USL-IRCCS of Reggio Emilia, Italy aff018;  Radiotherapy Unit, SS Annunziata Hospital—G. D'annunzio University, Chieti, Italy aff019;  Department of Diseases of the Thorax, Ospedale GB Morgagni, Forlì (I), Italy aff020;  Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Denmark aff021;  Department of General Thoracic Surgery, Catholic University, Rome, Italy aff022;  Department of Oncology, University of Turin, Torino, Italy aff023
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0224027

Souhrn

Concurrent chemotherapy and radiotherapy (cCRT) is considered the standard treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Unfortunately, management is still heterogeneous across different specialists. A multidisciplinary approach is needed in this setting due to recent, promising results obtained by consolidative immunotherapy. The aim of this survey is to assess current LA-NSCLC management in Italy. From January to April 2018, a 15-question survey focusing on diagnostic/therapeutic LA-NSCLC management was sent to 1,478 e-mail addresses that belonged to pneumologists, thoracic surgeons, and radiation and medical oncologists. 421 answers were analyzed: 176 radiation oncologists, 86 medical oncologists, 92 pneumologists, 64 thoracic surgeons and 3 other specialists. More than a half of the respondents had been practicing for >10 years after completing residency training. Some discrepancies were observed in clinical LA-NSCLC management: the lack of a regularly planned multidisciplinary tumor board, the use of upfront surgery in multistation stage IIIA, and territorial diffusion of cCRT in unresectable LA-NSCLC. Our analysis demonstrated good compliance with international guidelines in the diagnostic workup of LA-NSCLC. We observed a relationship between high clinical experience and good clinical practice. A multidisciplinary approach is mandatory for managing LA-NSCLC.

Klíčová slova:

Cancer detection and diagnosis – Cancer treatment – Diagnostic medicine – Lung and intrathoracic tumors – Non-small cell lung cancer – Oncology – Physicians – Surgical and invasive medical procedures


Zdroje

1. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90. doi: 10.1200/JCO.2009.26.2543 20351327

2. Glatzer M, Elicin O, Ramella S, Nestle U, Putora PM. Radio(chemo)therapy in locally advanced nonsmall cell lung cancer. Eur Respir Rev 2016; 25 : 65–70. doi: 10.1183/16000617.0053-2015 26929423

3. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323 : 940–945. doi: 10.1056/NEJM199010043231403 2169587

4. O’Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010; 6: CD002140.

5. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16 : 187–199. doi: 10.1016/S1470-2045(14)71207-0 25601342

6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311 : 899–909. [no author listed] 7580546

7. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. doi: 10.1056/NEJMoa1709937 28885881

8. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi: 10.1056/NEJMoa1809697 30280658

9. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787–98. doi: 10.1093/ejcts/ezu028 24578407

10. Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 2009;64 : 757–62. doi: 10.1136/thx.2008.109868 19454408

11. Chandra S, Nehra M, Agarwal D, Mohan A. Diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle biopsy in mediastinal lymphadenopathy: a systematic review and meta-analysis. Respir Care 2012;57 : 384–91. doi: 10.4187/respcare.01274 22004665

12. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21. doi: 10.1093/annonc/mdx222 28881918

13. Bilfinger TV, Albano D, Perwaiz M, Keresztes R, Nemesure B et al. Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach. Clin Lung Cancer. 2018;19 : 346–351. doi: 10.1016/j.cllc.2018.01.006 29506890

14. Crawford SM. Multidisciplinary team working contributes to lung cancer survival. BMJ. 2018;361:k1904. doi: 10.1136/bmj.k1904 29925606

15. Campbell BA, Ball D, Mornex F. Multidisciplinary lung cancer meetings: improving the practice of radiation oncology and facing future challenges. Respirology. 2015;20 : 192–8. doi: 10.1111/resp.12459 25581058

16. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374 : 379–386. doi: 10.1016/S0140-6736(09)60737-6 19632716

17. Pless M, Stupp R, Ris HR, Stahel RA, Weder W, Thierstein S et al. Induction chemoradiation in stage IIIA/ N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386 : 1049–1056. doi: 10.1016/S0140-6736(15)60294-X 26275735

18. Eberhardt WE, Pottgen C, Gauler TC, Friedel G, Veit S, Heinrich V et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33 : 4194–4201. doi: 10.1200/JCO.2015.62.6812 26527789


Článek vyšel v časopise

PLOS One


2019 Číslo 11
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Mepolizumab v reálné klinické praxi kurz
Mepolizumab v reálné klinické praxi
nový kurz
Autoři: MUDr. Eva Voláková, Ph.D.

BONE ACADEMY 2025
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D., doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Svět praktické medicíny 2/2025 (znalostní test z časopisu)

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#